KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $371.0 million.

  • Abbott Laboratories' Depreciation and Depletion rose 1208.46% to $371.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 571.43%. This contributed to the annual value of $1.3 billion for FY2024, which is 493.34% up from last year.
  • Abbott Laboratories' Depreciation and Depletion amounted to $371.0 million in Q3 2025, which was up 1208.46% from $357.0 million recorded in Q2 2025.
  • In the past 5 years, Abbott Laboratories' Depreciation and Depletion ranged from a high of $425.0 million in Q1 2021 and a low of $302.0 million during Q2 2023
  • Over the past 5 years, Abbott Laboratories' median Depreciation and Depletion value was $332.0 million (recorded in 2023), while the average stood at $338.2 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 5917.6% in 2021, then plummeted by 2682.35% in 2022.
  • Abbott Laboratories' Depreciation and Depletion (Quarter) stood at $369.0 million in 2021, then fell by 15.72% to $311.0 million in 2022, then grew by 6.75% to $332.0 million in 2023, then rose by 3.01% to $342.0 million in 2024, then grew by 8.48% to $371.0 million in 2025.
  • Its Depreciation and Depletion was $371.0 million in Q3 2025, compared to $357.0 million in Q2 2025 and $336.0 million in Q1 2025.